

## DAFTAR PUSTAKA

1. Widodo I, Dwianingsih EK, Triningsih E, Utoro T, Soeripto. Clinicopathological features of Indonesian breast cancers with different molecular subtypes. *Asian Pacific Journal of Cancer Prevention*. 2014;15(15):6109–13.
2. Cunningham FG, Leveno KJ, Bloom SL, Dashe JS, Hoffman BL, Casey BM, et al. The Puerperium. In: *Williams Obstetrics*, 25e. New York, NY: McGraw-Hill Education; 2018.
3. Sobotta J 1869 1945, Waschke J 1974. Buku ajar Anatomi Sobotta. 2017 Nov 14;
4. DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A. International variation in female breast cancer incidence and mortality rates. *Cancer Epidemiology Biomarkers and Prevention*. 2015 Oct 1;24(10):1495–506.
5. Hayes DF, Lippman ME. Chapter 75: Breast Cancer. In: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editors. *Harrison's Principles of Internal Medicine*, 20e. New York, NY: McGraw-Hill Education; 2018.
6. Suneja M, Szot JF, LeBlond RF, Brown DD. The Chest: Chest Wall, Pulmonary, and Cardiovascular Systems; The Breasts. In: *DeGowin's Diagnostic Examination*, 11e [Internet]. New York, NY: McGraw Hill; 2020. Available from: [accessmedicine.mhmedical.com/content.aspx?aid=1174040801](https://accessmedicine.mhmedical.com/content.aspx?aid=1174040801)

7. Global Cancer Observatory. Cancer Today : Breast Cancer Prevalence in Indonesia [Internet]. 2020 [cited 2021 Sep 30]. Available from: [https://gco.iarc.fr/today/online-analysis-pie?v=2020&mode=cancer&mode\\_population=continents&population=900&populations=360&key=total&sex=2&cancer=39&type=2&statistic=5&prevalence=1&population\\_group=0&ages\\_group%5B%5D=0&ages\\_group%5B%5D=17&nb\\_items=7&group\\_cancer=1&include\\_nmsc=1&include\\_nmsc\\_other=1&half\\_pie=0&donut=1](https://gco.iarc.fr/today/online-analysis-pie?v=2020&mode=cancer&mode_population=continents&population=900&populations=360&key=total&sex=2&cancer=39&type=2&statistic=5&prevalence=1&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group_cancer=1&include_nmsc=1&include_nmsc_other=1&half_pie=0&donut=1)
8. Global Cancer Observatory. Cancer Today : Breast Cancer Incidence in Indonesia [Internet]. 2020 [cited 2021 Sep 30]. Available from: [https://gco.iarc.fr/today/online-analysis-pie?v=2020&mode=cancer&mode\\_population=continents&population=900&populations=360&key=total&sex=2&cancer=39&type=0&statistic=5&prevalence=0&population\\_group=0&ages\\_group%5B%5D=0&ages\\_group%5B%5D=17&nb\\_items=7&group\\_cancer=1&include\\_nmsc=1&include\\_nmsc\\_other=1&half\\_pie=0&donut=1](https://gco.iarc.fr/today/online-analysis-pie?v=2020&mode=cancer&mode_population=continents&population=900&populations=360&key=total&sex=2&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group_cancer=1&include_nmsc=1&include_nmsc_other=1&half_pie=0&donut=1)
9. Global Cancer Observatory. Cancer Today : Breast Cancer Mortality Rate in Indonesia [Internet]. 2020 [cited 2021 Sep 30]. Available from: [https://gco.iarc.fr/today/online-analysis-pie?v=2020&mode=cancer&mode\\_population=continents&population=900&populations=360&key=total&sex=2&cancer=39&type=1&statistic=5&prevalence=0&population\\_group=0&ages\\_group%5B%5D=0&ages\\_group](https://gco.iarc.fr/today/online-analysis-pie?v=2020&mode=cancer&mode_population=continents&population=900&populations=360&key=total&sex=2&cancer=39&type=1&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group)

%5B%5D=17&nb\_items=7&group\_cancer=1&include\_nmsc=1&include\_nmsc\_other=1&half\_pie=0&donut=1

10. Desantis CE, Fedewa SA, Ann ;, Sauer G, Kramer JL, Smith RA, et al. Breast Cancer Statistics, 2015: Convergence of Incidence Rates Between Black and White Women. *CA Cancer J Clin.* 2016;66:31–42.
11. Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, et al. Risk factors and preventions of breast cancer. Vol. 13, *International Journal of Biological Sciences.* Ivyspring International Publisher; 2017. p. 1387–97.
12. Breast cancer [Internet]. 2021 [cited 2021 Aug 31]. Available from: <https://www.who.int/news-room/fact-sheets/detail/breast-cancer>
13. Alkabban FM, Ferguson T. Breast Cancer. *Cambridge Handbook of Psychology, Health and Medicine, Second Edition* [Internet]. 2021 Aug 7 [cited 2021 Aug 31];577–80. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK482286/>
14. Sonnenschein C, Soto AM. Carcinogenesis explained within the context of a theory of organisms. Vol. 122, *Progress in Biophysics and Molecular Biology.* Elsevier Ltd; 2016. p. 70–6.
15. Qian BZ, Pollard JW. Macrophage Diversity Enhances Tumor Progression and Metastasis. *Cell.* 2010 Apr 2;141(1):39–51.
16. Dumars C, Ngyuen JM, Gaultier A, Lanel R, Corradini N, Gouin F, et al. Oncotarget 78343 [www.impactjournals.com/oncotarget](http://www.impactjournals.com/oncotarget) Dysregulation of macrophage polarization is associated with the metastatic process in

- osteosarcoma [Internet]. Vol. 7, Oncotarget. 2016. Available from: [www.impactjournals.com/oncotarget/](http://www.impactjournals.com/oncotarget/)
17. S. Reksoprodjo A. Usia Dengan Tingkat Pengetahuan Tentang Kanker Payudara Dan Faktor Risikonya.
  18. Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various Types And Management Of Breast Cancer: An Overview. J Adv Pharm Technol Res [Internet]. 2010 Apr [cited 2021 Sep 29];1(2):109. Available from: [/pmc/articles/PMC3255438/](http://pmc/articles/PMC3255438/)
  19. Akram M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017;50:33.
  20. Wang Y, Acs B, Robertson S, Liu B, Solorzano L, Wählby C, et al. Improved breast cancer histological grading using deep learning. Annals of Oncology. 2022 Jan 1;33(1):89–98.
  21. What Breast Medical Oncologists Need From Pathologists: Overview, Tumor Size, Histologic Grade [Internet]. [cited 2022 May 26]. Available from: <https://emedicine.medscape.com/article/1668113-overview#a5>
  22. Nottingham Score for Breast Cancer [Internet]. 2022. Available from: [www.oncolink.org](http://www.oncolink.org)
  23. Kalli S, Semine A, Cohen S, Naber SP, Makim SS, Bahl M. American joint committee on cancer's staging system for breast cancer, eighth edition: What the radiologist needs to know. Radiographics. 2018 Nov 1;38(7):1921–33.

24. Rosen RD, Sapra A. TNM Classification. StatPearls NCBI [Internet]. 2022 Feb 17 [cited 2022 Aug 22]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK553187/>
25. Intan N, Wiguna P, Tjakra IB, Manuaba W. Karakteristik Pemeriksaan Imunohistokimia Pada Pasien Kanker Payudara Di Rsup Sanglah Periode 2003-2012. 2014.
26. van Asten K, Slembrouck L, Olbrecht S, Jongen L, Brouckaert O, Wildiers H, et al. Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. *Oncologist*. 2019 Feb 1;24(2):165–71.
27. Kementrian Kesehatan Republik Indonesia. Panduan Penatalaksanaan Kanker Payudara [Internet]. [cited 2022 Mar 8]. Available from: <http://kanker.kemkes.go.id/guidelines/PPKPayudara.pdf>
28. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival. *Clin Med Res*. 2009 Jun 1;7(1–2):4–13.
29. Vellaisamy G, Tirumalae R, Inchara Y. Expression of androgen receptor in primary breast carcinoma and its relation with clinicopathologic features, estrogen, progesterone, and her-2 receptor status. *J Cancer Res Ther*. 2019 Jul 1;15(5):989–93.
30. Joensuu K, Leidenius M, Kero M, Andersson LC, Horwitz KB, Heikkilä P. ER, PR, HER2, Ki-67 and CK5 in early and late relapsing breast cancer-

- reduced CK5 expression in metastases. *Breast Cancer (Auckl)*. 2013;7(1):23–34.
31. Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Vol. 5, *Genes and Diseases*. Chongqing yi ke da xue, di 2 lin chuang xue yuan Bing du xing gan yan yan jiu suo; 2018. p. 77–106.
  32. KBBI, entri : Umur.
  33. Sari SE, Harahap WA, Saputra D. Pengaruh Faktor Risiko Terhadap Ekspresi Reseptor Estrogen Pada Penderita Kanker Payudara Di Kota Padang [Internet]. Vol. 7, *Jurnal Kesehatan Andalas*. 2018. Available from: <http://jurnal.fk.unand.ac.id>
  34. Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. *Breast Cancer Res Treat* [Internet]. 2013 Jun [cited 2022 Mar 14];139(2):539. Available from: </pmc/articles/PMC3669503/>
  35. Soliman NA, Yussif SM. Ki-67 as a prognostic marker according to breast cancer molecular subtype. *Cancer Biol Med* [Internet]. 2016 Dec 1 [cited 2022 Jul 22];13(4):496. Available from: </pmc/articles/PMC5250608/>
  36. Article O, Yadav R, Sen R, Chauhan P. ER, PR, HER2/NEU Status And Relation To Clinicopathological Factors In Breast Carcinoma. 2016.

37. Ahadi M, Heibatollahi M, Zahedifard S. Comparison of er, pr, ki67 and her-2/neu reactivity pattern with patients' age, histologic grade, tumor size and lymph node status in invasive ductal breast cancer. *Int J Cancer Manag.* 2020 Jun 1;13(6):1–5.
38. Nigudgi S, Patil A, Karangadan S, K. Andola S. Association of Ki67 expression with clinicopathological parameters and molecular classification in invasive breast carcinomas. *Indian Journal of Pathology and Oncology.* 2019 Jun 28;6(2):207–12.
39. Shokouh TZ, Ezatollah A, Barand P. Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes Retrospective-Observational Analytical Study. 2015 [cited 2022 Dec 13];94. Available from: [www.md-journal.com](http://www.md-journal.com)